Nicolas A Nuñez1, Boney Joseph2, Mehak Pahwa1, Rakesh Kumar1, Manuel Gardea Resendez1, Larry J Prokop3, Marin Veldic1, Ashok Seshadri4, Joanna M Biernacka5, Mark A Frye1, Zhen Wang6, Balwinder Singh7. 1. Department of Psychiatry and Psychology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States. 2. Department of Neurology, Mayo Clinic, Rochester, MN, United States. 3. Mayo Medical Libraries, Mayo Clinic College of Medicine, Rochester, MN, United States. 4. Department of Psychiatry and Psychology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States; Department of Psychiatry and Psychology, Mayo Clinic Health System, Austin, MN, United States. 5. Department of Psychiatry and Psychology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States. 6. Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States; Evidence-Based Practice Center, Mayo Clinic, Rochester, MN, United States. 7. Department of Psychiatry and Psychology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States. Electronic address: singh.balwinder@mayo.edu.
Abstract
OBJECTIVE: To compare the efficacy and discontinuation of augmentation agents in adult patients with treatment-resistant depression (TRD). We conducted a systematic review and network meta-analyses (NMA) to combine direct and indirect comparisons of augmentation agents. METHODS: We included randomized controlled trials comparing one active drug with another or with placebo following a treatment course up to 24 weeks. Nineteen agents were included: stimulants, atypical antipsychotics, thyroid hormones, antidepressants, and mood stabilizers. Data for response/remission and all-cause discontinuation rates were analyzed. We estimated effect-size by relative risk using pairwise and NMA with random-effects model. RESULTS: A total of 65 studies (N = 12,415) with 19 augmentation agents were included in the NMA. Our findings from the NMA for response rates, compared to placebo, were significant for: liothyronine, nortriptyline, aripiprazole, brexpiprazole, quetiapine, lithium, modafinil, olanzapine (fluoxetine), cariprazine, and lisdexamfetamine. For remission rates, compared to placebo, were significant for: thyroid hormone(T4), aripiprazole, brexpiprazole, risperidone, quetiapine, and olanzapine (fluoxetine). Compared to placebo, ziprasidone, mirtazapine, and cariprazine had statistically significant higher discontinuation rates. Overall, 24% studies were rated as having low risk of bias (RoB), 63% had moderate RoB and 13% had high RoB. LIMITATIONS: Heterogeneity in TRD definitions, variable trial duration and methodological clinical design of older studies and small number of trials per comparisons. CONCLUSIONS: This NMA suggests a superiority of the regulatory approved adjunctive atypical antipsychotics, thyroid hormones, dopamine compounds (modafinil and lisdexamfetamine) and lithium. Acceptability was lower with ziprasidone, mirtazapine, and cariprazine. Further research and head-to-head studies should be considered to strengthen the best available options for TRD.
OBJECTIVE: To compare the efficacy and discontinuation of augmentation agents in adult patients with treatment-resistant depression (TRD). We conducted a systematic review and network meta-analyses (NMA) to combine direct and indirect comparisons of augmentation agents. METHODS: We included randomized controlled trials comparing one active drug with another or with placebo following a treatment course up to 24 weeks. Nineteen agents were included: stimulants, atypical antipsychotics, thyroid hormones, antidepressants, and mood stabilizers. Data for response/remission and all-cause discontinuation rates were analyzed. We estimated effect-size by relative risk using pairwise and NMA with random-effects model. RESULTS: A total of 65 studies (N = 12,415) with 19 augmentation agents were included in the NMA. Our findings from the NMA for response rates, compared to placebo, were significant for: liothyronine, nortriptyline, aripiprazole, brexpiprazole, quetiapine, lithium, modafinil, olanzapine (fluoxetine), cariprazine, and lisdexamfetamine. For remission rates, compared to placebo, were significant for: thyroid hormone(T4), aripiprazole, brexpiprazole, risperidone, quetiapine, and olanzapine (fluoxetine). Compared to placebo, ziprasidone, mirtazapine, and cariprazine had statistically significant higher discontinuation rates. Overall, 24% studies were rated as having low risk of bias (RoB), 63% had moderate RoB and 13% had high RoB. LIMITATIONS: Heterogeneity in TRD definitions, variable trial duration and methodological clinical design of older studies and small number of trials per comparisons. CONCLUSIONS: This NMA suggests a superiority of the regulatory approved adjunctive atypical antipsychotics, thyroid hormones, dopamine compounds (modafinil and lisdexamfetamine) and lithium. Acceptability was lower with ziprasidone, mirtazapine, and cariprazine. Further research and head-to-head studies should be considered to strengthen the best available options for TRD.
Authors: Richard C Shelton; Douglas J Williamson; Sara A Corya; Todd M Sanger; Luann E Van Campen; Michael Case; Susan D Briggs; Gary D Tollefson Journal: J Clin Psychiatry Date: 2005-10 Impact factor: 4.384
Authors: Gabor I Keitner; Steven J Garlow; Christine E Ryan; Philip T Ninan; David A Solomon; Charles B Nemeroff; Martin B Keller Journal: J Psychiatr Res Date: 2008-06-30 Impact factor: 4.791
Authors: Michael E Thase; James M Youakim; Aleksandar Skuban; Mary Hobart; Peter Zhang; Robert D McQuade; Margaretta Nyilas; William H Carson; Raymond Sanchez; Hans Eriksson Journal: J Clin Psychiatry Date: 2015-09 Impact factor: 4.384
Authors: Manisha Madhoo; Richard S E Keefe; Robert M Roth; Angelo Sambunaris; James Wu; Madhukar H Trivedi; Colleen S Anderson; Robert Lasser Journal: Neuropsychopharmacology Date: 2013-12-06 Impact factor: 7.853
Authors: Alexander J Goss; Muzaffer Kaser; Sergi G Costafreda; Barbara J Sahakian; Cynthia H Y Fu Journal: J Clin Psychiatry Date: 2013-11 Impact factor: 4.384